Revvity sets long-range growth targets, with 2027 guidance due on Q4 call

Revvity (RVTY) set long-range organic growth targets of 7% to 9% for Life Sciences and 5% to 7% for Diagnostics at its 2026 Investor Day.

Shares were little changed at 9:37 a.m. ET, from a $157.02 close.

The company expects 2026 revenue of about $2.9 billion, with Life Sciences about 55% and Diagnostics about 45%.

Segment targets

Life Sciences Solutions is targeted at 6% to 8% organic growth, and Signals Software at 10% to 12% on annualized portfolio value.

Immunodiagnostics is targeted at 7% to 9% growth, and Reproductive Health at 3% to 5%.

The long-term outlook shows 3% organic revenue growth, 200 basis points above market.

2027 considerations

Early 2027 assumptions: about 6% organic growth, net interest of about $85 million, a tax rate of about 19% and a flat share count.

Adjusted operating margin was about 28.8% in 2026. The future target is in the mid-30s%, with incremental adjusted operating margins in the low 40s%.

Formal 2027 guidance comes on the fourth-quarter earnings call.

Capital and cost actions

Revvity has about $5 billion of capital capacity through 2031 and has committed to an investment-grade credit rating.

It plans consistent share repurchases, maintains its dividend and will pursue targeted acquisitions to complement Life Sciences.

Headcount was cut about 16% from 2023 to 2026, and global square footage fell about 25% over the same period.

CEO Prahlad Singh said the company is "confident in our ability to deliver sustained, above-market growth and long-term shareholder value."